Search: onr:"swepub:oai:DiVA.org:uu-371540" > Myeloablative vs re...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 08184naa a2200805 4500 | |
001 | oai:DiVA.org:uu-371540 | |
003 | SwePub | |
008 | 190107s2018 | |||||||||||000 ||eng| | |
009 | oai:prod.swepub.kib.ki.se:142588656 | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3715402 URI |
024 | 7 | a https://doi.org/10.1182/bloodadvances.20180248442 DOI |
024 | 7 | a http://kipublications.ki.se/Default.aspx?queryparsed=id:1425886562 URI |
040 | a (SwePub)uud (SwePub)ki | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Chhabra, Saurabhu Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA4 aut |
245 | 1 0 | a Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia |
264 | c 2018-11-05 | |
264 | 1 | b American Society of Hematology,c 2018 |
338 | a print2 rdacarrier | |
520 | a Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment of chronic myeloid leukemia (CML). Optimal conditioning intensity for allo-HCT for CML in the era of tyrosine kinase inhibitors (TKIs) is unknown. Using the Center for International Blood and Marrow Transplant Research database, we sought to determine whether reduced-intensity/nonmyeloablative conditioning (RIC) allo-HCT and myeloablative conditioning (MAC) result in similar outcomes in CML patients. We evaluated 1395 CML allo-HCT recipients between the ages of 18 and 60 years. The disease status at transplant was divided into the following categories: chronic phase 1, chronic phase 2 or greater, and accelerated phase. Patients in blast phase at transplant and alternative donor transplants were excluded. The primary outcome was overall survival (OS) after allo-HCT. MAC (n = 1204) and RIC allo-HCT recipients (n = 191) from 2007 to 2014 were included. Patient, disease, and transplantation characteristics were similar, with a few exceptions. Multivariable analysis showed no significant difference in OS between MAC and RIC groups. In addition, leukemia-free survival and nonrelapse mortality did not differ significantly between the 2 groups. Compared with MAC, the RIC group had a higher risk of early relapse after allo-HCT (hazard ratio [HR], 1.85; P = .001). The cumulative incidence of chronic graft-versus-host disease (cGVHD) was lower with RIC than with MAC (HR, 0.77; P = .02). RIC provides similar survival and lower cGVHD compared with MAC and therefore may be a reasonable alternative to MAC for CML patients in the TKI era. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
700 | 1 | a Ahn, Kwang Woou Med Coll Wisconsin, Inst Hlth & Soc, Dept Biostat, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut |
700 | 1 | a Hu, Zhen-Huanu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut |
700 | 1 | a Jain, Sandeepu Med Univ South Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA4 aut |
700 | 1 | a Assal, Ameru Columbia Univ, Med Ctr, New York, NY USA4 aut |
700 | 1 | a Cerny, Janu UMass Mem Med Ctr, Worcester, MA USA4 aut |
700 | 1 | a Copelan, Edward A.u Carolinas HealthCare Syst, Levine Canc Inst, Dept Hematol Oncol & Blood Disorders, Charlotte, NC USA4 aut |
700 | 1 | a Daly, Andrewu Tom Baker Canc Clin, Calgary, AB, Canada4 aut |
700 | 1 | a DeFilipp, Zachariahu Massachusetts Gen Hosp, Blood & Marrow Transplant Program, Boston, MA 02114 USA4 aut |
700 | 1 | a Gadalla, Shahinaz M.u NCI, Div Canc Epidemiol & Genet, Clin Genet Branch, NIH, Rockville, MD USA4 aut |
700 | 1 | a Gale, Robert Peteru Imperial Coll London, Dept Med, Div Expt Med, Hematol Res Ctr, London, England4 aut |
700 | 1 | a Ganguly, Siddharthau Univ Kansas, Med Ctr, Div Hematol & Oncol, Blood & Marrow Transplantat, Kansas City, KS 66103 USA4 aut |
700 | 1 | a Hamilton, Betty K.u Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA4 aut |
700 | 1 | a Hildebrandt, Gerhard Carlu Univ Kentucky, Markey Canc Ctr, Lexington, KY USA4 aut |
700 | 1 | a Hsu, Jack W.u Shands HealthCare, Dept Med, Div Hematol & Oncol, Gainesville, FL USA;Univ Florida, Gainesville, FL USA4 aut |
700 | 1 | a Inamoto, Yoshihirou Natl Canc Ctr, Div Hematopoiet Stem Cell Transplantat, Tokyo, Japan4 aut |
700 | 1 | a Kanate, Abraham S.u West Virginia Univ, Osborn Hematopoiet Malignancy & Transplantat Prog, Morgantown, WV 26506 USA4 aut |
700 | 1 | a Khoury, H. Jeanu Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA4 aut |
700 | 1 | a Lazarus, Hillard M.u Case Western Reserve Univ, Univ Hosp Cleveland, Med Ctr, Seidman Canc Ctr, Cleveland, OH 44106 USA4 aut |
700 | 1 | a Litzow, Mark R.u Mayo Clin Rochester, Div Hematol & Transplant Ctr, Rochester, MN USA4 aut |
700 | 1 | a Nathan, Sunitau Rush Univ, Med Ctr, Chicago, IL 60612 USA4 aut |
700 | 1 | a Olsson, Richardu Karolinska Institutet,Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Div Therapeut Immunol, Stockholm, Sweden4 aut0 (Swepub:uu)riols677 |
700 | 1 | a Pawarode, Attapholu Univ Michigan, Dept Internal Med, Div Hematol Oncol, Med Sch,Blood & Marrow Transplantat Program, Ann Arbor, MI 48109 USA4 aut |
700 | 1 | a Ringden, Olleu Karolinska Institutet4 aut |
700 | 1 | a Rowe, Jacob M.u Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel4 aut |
700 | 1 | a Saad, Aymanu Univ Alabama Birmingham, Dept Med, Div Hematol Oncol, Birmingham, AL 35294 USA4 aut |
700 | 1 | a Savani, Bipin N.u Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, 221 Kirkland Hall, Nashville, TN 37235 USA4 aut |
700 | 1 | a Schouten, Harry C.u Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands4 aut |
700 | 1 | a Seo, Sachikou Natl Canc Res Ctr East, Dept Hematol & Oncol, Chiba, Japan4 aut |
700 | 1 | a Shah, Nirav N.u Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USA4 aut |
700 | 1 | a Solh, Melhemu Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA4 aut |
700 | 1 | a Stuart, Robert K.u Med Univ South Carolina, Dept Med, Div Hematol Oncol, Charleston, SC 29425 USA4 aut |
700 | 1 | a Ustun, Celalettinu Univ Minnesota, Med Ctr, Dept Med, Div Hematol Oncol & Transplantat, Minneapolis, MN 55455 USA4 aut |
700 | 1 | a Woolfrey, Ann E.u Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA4 aut |
700 | 1 | a Yared, Jean A.u Univ Maryland, Greenebaum Canc Ctr, Div Hematol Oncol, Blood & Marrow Transplantat Program,Dept Med, Baltimore, MD 21201 USA4 aut |
700 | 1 | a Alyea, Edwin P.u Dana Farber Canc Inst, Ctr Hematol Oncol, Boston, MA 02115 USA4 aut |
700 | 1 | a Kalaycio, Matt E.u Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA4 aut |
700 | 1 | a Popat, Udayu Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA4 aut |
700 | 1 | a Sobecks, Ronald M.u Cleveland Clin Fdn, Dept Hematol & Med Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA4 aut |
700 | 1 | a Saber, Waelu Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 aut |
710 | 2 | a Med Coll Wisconsin, Dept Med, Div Hematol Oncol, 9200 W Wisconsin Ave, Milwaukee, WI 53226 USAb Med Coll Wisconsin, Inst Hlth & Soc, Dept Biostat, Milwaukee, WI 53226 USA;Med Coll Wisconsin, Dept Med, Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI 53226 USA4 org |
773 | 0 | t Blood Advancesd : American Society of Hematologyg 2:21, s. 2922-2936q 2:21<2922-2936x 2473-9529x 2473-9537 |
856 | 4 | u https://europepmc.org/articles/pmc6234373?pdf=render |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-371540 |
856 | 4 8 | u https://doi.org/10.1182/bloodadvances.2018024844 |
856 | 4 8 | u http://kipublications.ki.se/Default.aspx?queryparsed=id:142588656 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.